New hope for kids with tough cancers: ponatinib trial launches
NCT ID NCT03934372
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 5 times
Summary
This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 children will take part across multiple hospitals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ponatinib (a targeted cancer drug)
- What this could lead to
- If it works, this could provide a new treatment option for children with hard-to-treat cancers that have not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 70 participants, so results may not apply to all children. The drug can cause serious side effects like blood clots and liver problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita
RECRUITINGTorino, 10126, Italy
-
Alder Hey Childrens Nhs Foundation Trust
RECRUITINGLiverpool, L12 2AP, United Kingdom
-
Aorn Santobono Pausilipon
NOT_YET_RECRUITINGNaples, 80122, Italy
-
Aou Policlinico S. Orsola-Malpighi
RECRUITINGBologna, 40138, Italy
-
Armand Trousseau Hospital
RECRUITINGParis, 75571, France
-
Asst Degli Spedali Civili Di Brescia
RECRUITINGBrescia, 25123, Italy
-
Centre Hospitalier Universitaire de Poitiers
RECRUITINGPoitiers, 86021, France
-
Chu de Rennes - Hospital Sud
COMPLETEDRennes, 35700, France
-
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
RECRUITINGPavia, 27100, Italy
-
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
RECRUITINGMilan, 20133, Italy
-
Ghent University Hospital
RECRUITINGGhent, 09000, Belgium
-
Hopital Robert Debre
RECRUITINGParis, 75019, France
-
Hospital General Universitario Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Infantil Unversitario Nino Jesus
RECRUITINGMadrid, 28009, Spain
-
Hospital Sant Joan de Deu de Manresa
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitari I Politecnic La Fe
RECRUITINGValencia, 46026, Spain
-
Karolinska University Hospital Solna
RECRUITINGStockholm, 14141, Sweden
-
Ospedale Pediatrico Bambino Gesu Irccs
RECRUITINGRome, 00165, Italy
-
Ospedale Pediatrico G. Gaslini
RECRUITINGGenova, 16147, Italy
-
Princess Maxima Center For Pediatric Oncology
RECRUITINGUtrecht, 03584, Netherlands
-
Royal Hospital For Sick Children Yorkhill Glasgow
RECRUITINGGlasgow, G514TF, United Kingdom
-
The Royal Marsden Nhs Foundation Trust - Sutton
RECRUITINGSutton, SM2 5PT, United Kingdom
-
University of Milano Bicocca
RECRUITINGMonza, 20900, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?